Advertisement

Neurological Sciences

, Volume 24, Issue 6, pp 420–423 | Cite as

Treatment of phonic tics in patients with Tourette’s syndrome using botulinum toxin type A

  • M. PortaEmail author
  • G. Maggioni
  • F. Ottaviani
  • A. Schindler
BRIEF COMMUNICTION

Abstract.

We assessed the effect of botulinum toxin type A (BTX-A) on phonic tics in patients with Tourette’s syndrome. A total of 30 patients received 2.5 IU BTX-A (BOTOX; Allergan) in both vocal cords. All patients were assessed after 15 days and then 4 times over a 12-month period. At each visit the following data were collected: phenomenology of tics, global impression of changes by physician and patient, number of BTX-A injections given, interval between injections, time to response, duration of response, presence of post-injection hypophonia and side effects, presence of premonitory sensory tic component, and interference with social life and work or school activities. Vocal tics improved after treatment in 93% patients, with 50% being tic-free. Mean response time was 5.8 days, and mean duration of response was 102 days. Quality of life improved, and premonitory experiences dropped from 53% to 20%. Hypophonia was the only side effect of note (80% of patients). BTX-A is an effective and safe treatment for phonic tics associated with Tourette’s syndrome.

Keywords

Botulinum toxin type A Botox Tourette’s syndrome Phonic tics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • M. Porta
    • 1
    Email author
  • G. Maggioni
    • 1
  • F. Ottaviani
    • 2
  • A. Schindler
    • 2
  1. 1.Department of NeurologyPoliclinico San MarcoZingonia (BG)Italy
  2. 2.ENT Department, Sacco HospitalUniversity of MilanMilanItaly

Personalised recommendations